List of Janssen Biotech patents

Patents where

Current Assignee

Name

Janssen Biotech

Name	Description	Patent Applicant	Current Assignee	Patent Jurisdiction	Patent Number	Date of Patent
‌ US Patent 9925088 Sub-retinal tangential needle catheter guide and introducer	Patent 9925088 was granted and assigned to Janssen Biotech on March, 2018 by the United States Patent and Trademark Office.	Janssen Biotech	Janssen Biotech	United States Patent and Trademark Office	9925088	March 27, 2018
‌ US Patent 11780911 Method of treating inflammatory bowel disease with a combination therapy of antibodies to IL-23 and TNF alpha	Patent 11780911 was granted and assigned to Janssen Biotech on October, 2023 by the United States Patent and Trademark Office.	Janssen Biotech	Janssen Biotech	United States Patent and Trademark Office	11780911	October 10, 2023
‌ US Patent 10196446 Cysteine engineered fibronectin type III domain binding molecules	Patent 10196446 was granted and assigned to Janssen Biotech on February, 2019 by the United States Patent and Trademark Office.	Janssen Biotech	Janssen Biotech	United States Patent and Trademark Office	10196446	February 5, 2019
‌ US Patent 11603405 Anti-CD3 antibodies and uses thereof	Patent 11603405 was granted and assigned to Janssen Biotech on March, 2023 by the United States Patent and Trademark Office.	Janssen Biotech	Janssen Biotech	United States Patent and Trademark Office	11603405	March 14, 2023
‌ US Patent 9683046 Nucleic acid molecules encoding anti-CD27 antibodies	Patent 9683046 was granted and assigned to Janssen Biotech on June, 2017 by the United States Patent and Trademark Office.	Janssen Biotech	Janssen Biotech	United States Patent and Trademark Office	9683046	June 20, 2017
‌ US Patent 11538167 Method for determining severity of skin disease based on percentage of body surface area covered by lesions	Patent 11538167 was granted and assigned to Janssen Biotech on December, 2022 by the United States Patent and Trademark Office.	Janssen Biotech	Janssen Biotech	United States Patent and Trademark Office	11538167	December 27, 2022
‌ US Patent 11618787 Methods of treating high risk multiple myeloma	Patent 11618787 was granted and assigned to Janssen Biotech on April, 2023 by the United States Patent and Trademark Office.	Janssen Biotech	Janssen Biotech	United States Patent and Trademark Office	11618787	April 4, 2023
‌ US Patent 10494609 Use of a TGF-βR-1 kinase to produce human pancreatic endocrine cells	Patent 10494609 was granted and assigned to Janssen Biotech on December, 2019 by the United States Patent and Trademark Office.	Janssen Biotech	Janssen Biotech	United States Patent and Trademark Office	10494609	December 3, 2019
‌ US Patent 11576986 Macrocyclic chelators and methods of use thereof	Patent 11576986 was granted and assigned to Janssen Biotech on February, 2023 by the United States Patent and Trademark Office.	Janssen Biotech	Janssen Biotech	United States Patent and Trademark Office	11576986	February 14, 2023
‌ US Patent 11713355 Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia	Patent 11713355 was granted and assigned to Janssen Biotech on August, 2023 by the United States Patent and Trademark Office.	Janssen Biotech	Janssen Biotech	United States Patent and Trademark Office	11713355	August 1, 2023
‌ US Patent 11505783 Differentiation of human embryonic stem cells	Patent 11505783 was granted and assigned to Janssen Biotech on November, 2022 by the United States Patent and Trademark Office.	Janssen Biotech	Janssen Biotech	United States Patent and Trademark Office	11505783	November 22, 2022
‌ US Patent 8951525 Human tissue factor antibody and uses thereof	Patent 8951525 was granted and assigned to Janssen Biotech on February, 2015 by the United States Patent and Trademark Office.	Janssen Biotech	Janssen Biotech	United States Patent and Trademark Office	8951525	February 10, 2015
‌ US Patent 9862766 Method of treating lupus by administering an anti-IL-12 antibody	Patent 9862766 was granted and assigned to Janssen Biotech on January, 2018 by the United States Patent and Trademark Office.	Janssen Biotech	Janssen Biotech	United States Patent and Trademark Office	9862766	January 9, 2018
‌ US Patent 12009079 Type I interferon signatures and methods of use	Patent 12009079 was granted and assigned to Janssen Biotech on June, 2024 by the United States Patent and Trademark Office.	Janssen Biotech	Janssen Biotech	United States Patent and Trademark Office	12009079	June 11, 2024
‌ US Patent 10336812 GDF15 fusion proteins and uses thereof	Patent 10336812 was granted and assigned to Janssen Biotech on July, 2019 by the United States Patent and Trademark Office.	Janssen Biotech	Janssen Biotech	United States Patent and Trademark Office	10336812	July 2, 2019
‌ US Patent 9593307 Defined media for expansion and maintenance of pluripotent stem cells	Patent 9593307 was granted and assigned to Janssen Biotech on March, 2017 by the United States Patent and Trademark Office.	Janssen Biotech	Janssen Biotech	United States Patent and Trademark Office	9593307	March 14, 2017
‌ US Patent 8975040 Methods and vectors for generating asialylated immunoglobulins	Patent 8975040 was granted and assigned to Janssen Biotech on March, 2015 by the United States Patent and Trademark Office.	Janssen Biotech	Janssen Biotech	United States Patent and Trademark Office	8975040	March 10, 2015
‌ US Patent 11708420 Subcutaneous formulations of anti-CD38 antibodies and their uses	Patent 11708420 was granted and assigned to Janssen Biotech on July, 2023 by the United States Patent and Trademark Office.	Janssen Biotech	Janssen Biotech	United States Patent and Trademark Office	11708420	July 25, 2023
‌ US Patent 11708419 Subcutaneous formulations of anti-CD38 antibodies and their uses	Patent 11708419 was granted and assigned to Janssen Biotech on July, 2023 by the United States Patent and Trademark Office.	Janssen Biotech	Janssen Biotech	United States Patent and Trademark Office	11708419	July 25, 2023
‌ US Patent 8722618 IL4/IL13 binding repeat proteins and uses	Patent 8722618 was granted and assigned to Janssen Biotech on May, 2014 by the United States Patent and Trademark Office.		Janssen Biotech	United States Patent and Trademark Office	8722618	May 13, 2014
‌ US Patent 9695228 EGFR and c-Met fibronectin type III domain binding molecules	Patent 9695228 was granted and assigned to Janssen Biotech on July, 2017 by the United States Patent and Trademark Office.	Janssen Biotech	Janssen Biotech	United States Patent and Trademark Office	9695228	July 4, 2017
‌ US Patent 9593305 Differentiation of pluripotent stem cells	Patent 9593305 was granted and assigned to Janssen Biotech on March, 2017 by the United States Patent and Trademark Office.		Janssen Biotech	United States Patent and Trademark Office	9593305	March 14, 2017
‌ US Patent 9593306 Differentiation of pluripotent stem cells	Patent 9593306 was granted and assigned to Janssen Biotech on March, 2017 by the United States Patent and Trademark Office.		Janssen Biotech	United States Patent and Trademark Office	9593306	March 14, 2017
‌ US Patent 11466082 Anti-CD33 antibodies, anti-CD33/anti-CD3 bispecific antibodies and uses thereof		Janssen Biotech	Janssen Biotech	United States Patent and Trademark Office	11466082	October 11, 2022
‌ US Patent 8080247 Anti-IL-12 antibodies	Patent 8080247 was granted and assigned to Janssen Biotech on December, 2011 by the United States Patent and Trademark Office.		Janssen Biotech	United States Patent and Trademark Office	8080247	December 20, 2011

...

Results per page:

315 results

0 selected

315 results

0 selected